Danielle Gilliam on FDA’s Approval of Wegovy Pill from Novo Nordisk
Danielle Gilliam, Executive Medical Science Liaison Cardiovascular and Renal at Novo Nordisk North America, shared on LinkedIn:
”The FDA’s approval also clears the pill for use to reduce the risk of major cardiovascular events, such as death, heart attack or stroke, in adults with obesity and established cardiovascular disease, according to Novo Nordisk.”
Find more here.
Read the full announcement by Novo Nordisk here.
Novo Nordisk announced that the US Food and Drug Administration has approved the Wegovy pill, a once-daily oral semaglutide 25 mg, for long-term weight reduction and maintenance, as well as for reducing the risk of major adverse cardiovascular events.
The oral formulation is indicated for adults with obesity or overweight who have at least one weight-related comorbidity, and for adults with established heart disease to lower the risk of death, heart attack, or stroke.
In addition, Wegovy injection is approved for chronic weight management in paediatric patients aged 12 years and older.
The injectable form is also approved for the treatment of MASH in adults with moderate to advanced liver fibrosis, excluding those with cirrhosis.
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM
-
Aug 26, 2026, 13:59David McIntosh: Immunoglobulin Stewardship in the Face of Rising Demand
-
Aug 26, 2026, 13:54Giuseppe Biondi Zoccai: Congratulations to the Next Editor-in-Chief of the EHJ
-
Aug 26, 2026, 13:25Omar Adwan: Abnormal Nuclear Morphology of Neutrophil
-
Aug 26, 2026, 13:05Preventing Thrombosis with WTDay26
-
Aug 26, 2026, 10:09Gemma Figtree: How Well Do We Predict Heart Attack Risk in Women?
-
Aug 26, 2026, 10:06Understanding and Managing Fatigue in ITP – ITP Support Association
-
Aug 26, 2026, 10:04Abdul Muqtadir Abbasi: When a High INR Hides a Thrombotic Cancer
-
Aug 26, 2026, 09:42Mohammed Alo: What’s Wrong With the New Blood Pressure Guidelines?